- Report
- May 2024
- 137 Pages
Global
From €5907EUR$6,499USD£5,058GBP
- Report
- May 2024
- 139 Pages
Global
From €5907EUR$6,499USD£5,058GBP
- Report
- September 2024
- 121 Pages
North America
From €5408EUR$5,950USD£4,631GBP
- Report
- April 2023
- 116 Pages
Global
From €4090EUR$4,500USD£3,502GBP
- Report
- October 2022
- 120 Pages
Global
From €4090EUR$4,500USD£3,502GBP
- Report
- August 2022
- 167 Pages
Global
From €8635EUR$9,500USD£7,394GBP
- Report
- August 2022
- 83 Pages
Global
From €4317EUR$4,750USD£3,697GBP
- Report
- July 2022
- 184 Pages
Global
From €8635EUR$9,500USD£7,394GBP
- Clinical Trials
- April 2024
- 80 Pages
Global
€2272EUR$2,500USD£1,946GBP
- Report
- October 2023
- 90 Pages
United States
From €3181EUR$3,500USD£2,724GBP
- Report
- April 2025
- 50 Pages
Global
From €2409EUR$2,650USD£2,062GBP
Imiquimod is a topical cream used in the treatment of dermatological conditions such as actinic keratosis, superficial basal cell carcinoma, and genital warts. It is a member of the immune response modifier family of drugs, which work by stimulating the body's own immune system to fight the virus or cancer cells. Imiquimod is available in both prescription and over-the-counter forms.
Imiquimod is a popular choice for treating dermatological conditions due to its effectiveness and low risk of side effects. It is also relatively inexpensive compared to other treatments. Imiquimod is typically applied directly to the affected area, and can be used in combination with other treatments such as surgery or radiation.
The Imiquimod market is highly competitive, with many companies offering their own versions of the drug. Some of the major players in the market include 3M, GlaxoSmithKline, Mylan, and Teva Pharmaceuticals. Other companies such as Galderma, Merck, and Sun Pharmaceuticals also offer Imiquimod products. Show Less Read more